Following these proceedings, Rodman & Renshaw initiated its Heron Therapeutics Inc [HRTX] rating to a Buy in a research note published on June 13, 2024; the price target was $7. A number of analysts have revised their coverage, including CapitalOne’s analysts, who began to cover the stock in late April with a ‘”an Overweight”‘ rating. Needham also remained covering HRTX and reiterated its “Buy” recommendation on March 13, 2024. Guggenheim started covering the stock on May 27, 2020. It rated HRTX as “a Buy”.
Price Performance Review of HRTX
On Monday, Heron Therapeutics Inc [NASDAQ:HRTX] saw its stock fall -2.84% to $2.05. Over the last five days, the stock has lost -3.76%. Heron Therapeutics Inc shares have risen nearly 33.99% since the year began. Nevertheless, the stocks have fallen -31.89% over the past one year. While a 52-week high of $3.93 was reached on 03/05/25, a 52-week low of $1.04 was recorded on 01/14/25. SMA at 50 days reached $2.21, while 200 days put it at $1.90.
Levels Of Support And Resistance For HRTX Stock
The 24-hour chart illustrates a support level at 2.00, which if violated will result in even more drops to 1.94. On the upside, there is a resistance level at 2.15. A further resistance level may holdings at 2.24. The Relative Strength Index (RSI) on the 14-day chart is 44.82, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.15, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 91.82%. Stochastics %K at 24.61% indicates the stock is a holding.
The most recent change occurred on February 20, 2020 when Needham resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $48.
